What are the Medicare coverage rules and real-world cost implications for patients prescribed Leqembi or donanemab?
Executive summary
Medicare covers FDA‑approved monoclonal antibody Alzheimer’s drugs such as Leqembi (lecanemab) — and will cover donanemab (Kisunla) if it receives traditional FDA approval — under Part B provided clinicians participate in a CMS data registry, with beneficiaries generally responsible for 20% coinsurance after the Part B deductible (CMS; Alzheimer’s Association) [1] [2]. The real‑world financial picture for patients combines that coinsurance with high list prices (reported around $26,000–$27,500 per year), variable deductibles across years, potential supplemental coverage, limited specialist capacity, and systemwide cost pressures that could raise premiums and taxpayer spending (Healthline; Drugs.com; CMS actuaries; CBS/Stat) [3] [4] [5] [6].
1. Coverage rules — the narrow print that matters
Medicare’s current policy pays for traditionally approved monoclonal antibody Alzheimer’s drugs under Part B if treating clinicians enter patients’ data into a CMS‑facilitated registry and meet program requirements for clinical care and follow‑up, a condition CMS explicitly attached to broader coverage after FDA traditional approval (CMS; Alzheimer’s Association) [1] [2]. Original Medicare beneficiaries receiving these infusions will generally face the standard Part B cost‑sharing: 20% of the Medicare‑approved amount after satisfying the annual Part B deductible, though exact dollar exposure depends on that year’s deductible and whether a beneficiary carries Medigap, secondary insurance, or a Medicare Advantage plan (CMS; California Health Advocates) [1] [7]. Medicare Advantage plans must, in practice, match Original Medicare benefits, but administrative rules and prior authorization practices can create additional access hurdles (Forbes; MedicareFAQ) [8] [9].
2. What patients actually pay — sticker price vs. pocket price
Manufacturers’ list prices for Leqembi have been reported around $26,500–$27,439 per year for typical dosing, meaning a beneficiary without supplemental coverage could face roughly 20% of that annually after the Part B deductible — tens of thousands of dollars before subsidies — although many will pay less if they have Medigap or other secondary payers (Healthline; Drugs.com; CMS) [3] [4] [1]. Published year‑to‑year deductible figures vary (examples cited: $226 in 2023, $257 in 2025, $283 in 2026), so exact out‑of‑pocket totals shift with policy years and individual coverage (California Health Advocates; Forbes; Drugs.com) [7] [8] [4]. Manufacturers and patient‑support programs may offer assistance, but those programs typically exclude government‑insured patients from certain copay assistance and cannot change Medicare’s coinsurance rules (Drugs.com) [4].
3. Access and non‑price costs that amplify financial strain
Beyond drug coinsurance, treating patients incurs diagnostic and monitoring costs — PET scans, blood tests, genetic and neuropsychological testing, and frequent infusion visits — and a constrained workforce of specialists may delay initiation of therapy; those associated costs and logistics can add materially to what patients and Medicare pay (CBS; Stat) [6] [5]. The Inflation Reduction Act’s $2,000 Part D cap does not reduce Part B exposure, leaving Leqembi and similar infusions outside that particular protection and exposing beneficiaries to higher effective cost sharing unless they have supplemental coverage (CBS) [10].
4. Systemwide cost implications and political pressure
Medicare actuaries projected that Leqembi alone could cost traditional Medicare roughly $550 million in 2024 and up to $3.5 billion for the entire Medicare program in 2025, figures that sparked debate about premium impacts and long‑term sustainability and fed advocacy and political pressure over pricing and coverage rules (Stat; AARP) [5] [11]. Analysts and consumer groups have warned the rollout could push Part B premiums higher over time, and advocacy organizations stress that Medicaid and state programs may vary in coverage, creating geographic inequities (Politico; NCOA) [12] [13].
5. Uncertainties, incentives and why different stakeholders see different risks
Clinical uncertainty about long‑term effectiveness and safety of amyloid‑targeting antibodies fuels cautious uptake among clinicians and payers even as manufacturers and patient groups push for access; CMS’s registry requirement is both a data‑gathering tool and a cost‑control measure that reflects this tension (NCOA; CMS) [13] [2]. Drugmakers and some advocates emphasize therapeutic benefit and patient demand, while budget‑conscious analysts and taxpayer advocates highlight high list prices and potential premium impacts; both perspectives are grounded in evidence cited by CMS and independent actuarial estimates (CBS; Stat) [6] [5].